Dr. Beiyan Zhou's lab focuses on understanding how type 2 diabetes (T2DM) increases the risk of atherosclerotic cardiovascular disease (ASCVD). By using innovative computational programs and biological tools, the lab investigates the mechanisms that lead to elevated ASCVD risk in T2DM patients. The goal is to develop predictive models and potential treatment options that can better manage ASCVD risks in individuals with T2DM.

Dr. Stephen M. King's lab at the University of Connecticut focuses on the biology of motile cilia, which are tiny hair-like structures that help cells move and communicate. They conduct research using the green alga Chlamydomonas to understand how cilia are formed, how they beat, and how they release signals that affect other cells. The lab aims to discover new mechanisms involved in ciliary movement and the role of peptide signals in cell interactions, which are important for proper human development and health.

Dr. Joel Pachter's lab focuses on understanding meningeal ectopic lymphoid tissues (mELTs), which are clusters of immune cells that appear in the brains of patients with progressive multiple sclerosis (MS). Their research seeks to explore how these structures contribute to neuroinflammation and neurodegeneration during MS. By utilizing advanced imaging and transcriptomic techniques, the lab aims to uncover the cellular composition and gene expression patterns of mELTs to identify new therapeutic targets for treating MS.

Dr. Penghua Wang's lab focuses on understanding the role of non-canonical inflammasomes in the immune response, particularly during infections that can lead to severe illnesses like sepsis. By studying how specific proteins, such as UBXN1, regulate inflammation, the lab aims to uncover new pathways that could lead to better treatments for sepsis and related inflammatory diseases.